Pieris Pharmaceuticals Liabilities 2024

Pieris Pharmaceuticals Aktienanalyse

What does Pieris Pharmaceuticals do?

Pieris Pharmaceuticals Inc is a biotechnology company that focuses on the development of therapeutic antibodies. The company was founded in 2001 in Freising, Germany, and has since relocated its headquarters to Boston, USA. The company's history traces back to the research group of Professor Arne Skerra at the Technical University of Munich, which specialized in the development of new protein engineering technologies. Together with another biotech company, Swiss CYTHERIS SA, they eventually founded Pieris Pharmaceuticals Inc. The company received $10 million in funding in 2004 from international investors, including some German funds. Since then, the company has had several successful IPOs and has become one of the leading biotech companies in antibody research. The business model of Pieris Pharmaceuticals is based on the development and commercialization of antibodies that can be used as therapeutics for various diseases. The company combines its own research and development efforts with partnerships with other companies and organizations. The company's divisions include the development of antibodies for the treatment of cancer and immune-related diseases, the development of antibodies to combat infectious diseases, and the development of novel antibody platforms to generate broad antibody spectra. One of Pieris Pharmaceuticals' most successful products is the antibody PRS-343, which was developed as a therapeutic for HER2-positive breast cancer. A study showed that PRS-343, in combination with the chemotherapy drug Herceptin, has a higher efficacy than Herceptin alone. Another promising project is the development of an antibody for the treatment of tumors in the gastrointestinal tract. The substance PRS-276 is able to selectively attack and kill these cells due to its high affinity to the tumor antigen Claudin18.2. Overall, Pieris Pharmaceuticals Inc has launched numerous successful projects in recent years and has expanded its competitive position in the biotech industry. The company aims to closely collaborate with partners from the pharmaceutical industry to accelerate and optimize the development and commercialization of its products. Pieris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Pieris Pharmaceuticals's Liabilities

Pieris Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pieris Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pieris Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pieris Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pieris Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pieris Pharmaceuticals stock

What is the level of liabilities of Pieris Pharmaceuticals this year?

Pieris Pharmaceuticals has a debt balance of 11.92 M USD this year.

What were the liabilities of Pieris Pharmaceuticals compared to the previous year?

The liabilities of Pieris Pharmaceuticals have increased by -82.35% dropped compared to the previous year.

What are the consequences of high debt for investors of Pieris Pharmaceuticals?

High liabilities can pose a risk for investors of Pieris Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Pieris Pharmaceuticals?

Low liabilities mean that Pieris Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Pieris Pharmaceuticals affect the company?

An increase in liabilities of Pieris Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Pieris Pharmaceuticals affect the company?

A decrease in the liabilities of Pieris Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Pieris Pharmaceuticals?

Some factors that can influence the liabilities of Pieris Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Pieris Pharmaceuticals so important for investors?

The liabilities of Pieris Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Pieris Pharmaceuticals take to modify the liabilities?

To change its liabilities, Pieris Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Pieris Pharmaceuticals pay?

Over the past 12 months, Pieris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pieris Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Pieris Pharmaceuticals?

The current dividend yield of Pieris Pharmaceuticals is .

When does Pieris Pharmaceuticals pay dividends?

Pieris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pieris Pharmaceuticals?

Pieris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Pieris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pieris Pharmaceuticals located?

Pieris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pieris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pieris Pharmaceuticals from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Pieris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Pieris Pharmaceuticals in the year 2023?

In the year 2023, Pieris Pharmaceuticals distributed 0 USD as dividends.

In which currency does Pieris Pharmaceuticals pay out the dividend?

The dividends of Pieris Pharmaceuticals are distributed in USD.